Home › Leucemia acuta bifenotipica › Washington
Studi clinici su Leucemia acuta bifenotipica nello stato di Washington
15 studi su Leucemia acuta bifenotipica cercano partecipanti presso sedi nello stato di Washington.
Città nello stato di Washington
Testo ufficiale dello studio (inglese)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età da 12 a 78 · Tutti i sessi · Aggiornato il 29 set 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04375631Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07094750Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- e altri 1
In reclutamentoFase 1/2
Fino a 22 anni · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04726241Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 2
6 Months – 65 Years · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 lug 2026 · NCT07046078211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1/2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1/2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT03670966Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 2Volontari sani benvenuti
6 Months · Tutti i sessi · Aggiornato il 29 mag 2026 · NCT04195633HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1
Fino a 80 anni · Tutti i sessi · Aggiornato il 18 mag 2026 · NCT03326921Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1/2Volontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 mag 2026 · NCT06928662Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 apr 2026 · NCT04797767Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Seattle Children's Hospital, Seattle
In reclutamentoFase 1
Età da 1 a 21 · Tutti i sessi · Aggiornato il 6 dic 2024 · NCT05476770Fonte: ClinicalTrials.gov, dati recuperati il 3 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.